Biotech Catches Major Premarket Bid

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, January 10, 2023

A New Jersey-based biotech company is turning heads on Tuesday after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201.

This press release caused shares of VYNE Therapeutics Inc. (Nasdaq:VYNE) to be bid up during Tuesday’s premarket as traders are currently willing to buy at $0.3057/share (+59.22% implied open for sellers) at the time of writing. This move will be a strong continuation of the success this micro cap has had so far this year.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ and ZILXI.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.